Over control of proliferation of tumor-initiating cells, delaying relapse in cancer patients
It has been possible to synthesize a new molecule inhibiting self-renewal of tumour initiating cell. It increases the efficiency and effectiveness of chemotherapeutic treatments by reducing the drugs up to half the dose, with identical results and lower side effects for the patient. In addition, this molecule could facilitate the option to the health professional for a personalized treatment, increasing doses and cycles in the cases in which it is necessary. Guaranteeing the economic optimization to the health system. The results have been verified in three of the tumour types with higher population incidence and higher mortality and morbidity (colon, breast and cerebral GBM cancer).
C-ter PEDF is a regulator of cell division kinetics, capable of removing tumor initiating cells from their quiescence, making cell division faster and better responding to chemotherapy.
Therefore, combined with current anti-neoplastic treatments make them more effective and efficient, because allow a reduction of the chemotherapy dose administered to each patient with the consequent decrease in side effects. So that, for the same response il will be needed half doses saving also costs to the sanitary system .
“New paradigm in the fight against cancer and relapse of patients already treated: elimination of tumor initiator cells”
Health
Biotechnology (Health Research)
“Relapses in patients produce tumors of greater aggressiveness and dissemination to other organs by metastasis. Metastases are the leading cause of death from cancer”
Health
Biotechnology (Health Research)
C-ter PEDF Contact
Carmen Ramírez-Castillejo
e: mariadelcarmen.ramirez@upm.es
UPM contact
Innovation, Commercialization and Entrepreneurship Area
Centre of Support for Technological Innovation – UPM
e: innovacion.tecnologica@upm.es